The performance of this mRNA signature analysis by qRT-PCR also compares favourably with protein signature analysis by immunohistochemistry, the current clinical practice standard, which has shown 78–87% accuracy in identifying RCC samples using AMACR, CK7, and CD10 [35]. This evidence concerns the gene AMACR and renal cell adenocarcinoma.